Mr. FiaWe now own 50% of Torion which is where the Covisafe technology will reside. Our agreement was to develop the technology and move it to commercial viability which is what we are doing now. Pilot testing moves it closer to achieving regulatory approval which allows us to sell the product in the future. There are other partners that brought the IP to the table who receive the other 50% of Torion. That IP resides in Torion.